Logo image of TNDM

TANDEM DIABETES CARE INC (TNDM) Stock Fundamental Analysis

NASDAQ:TNDM - Nasdaq - US8753722037 - Common Stock - Currency: USD

20.7  -0.06 (-0.29%)

Fundamental Rating

3

TNDM gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. TNDM has a bad profitability rating. Also its financial health evaluation is rather negative. TNDM is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year TNDM has reported negative net income.
TNDM had a positive operating cash flow in the past year.
TNDM had negative earnings in 4 of the past 5 years.
Of the past 5 years TNDM 4 years had a positive operating cash flow.
TNDM Yearly Net Income VS EBIT VS OCF VS FCFTNDM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

The Return On Assets of TNDM (-19.94%) is comparable to the rest of the industry.
TNDM has a worse Return On Equity (-118.40%) than 66.31% of its industry peers.
Industry RankSector Rank
ROA -19.94%
ROE -118.4%
ROIC N/A
ROA(3y)-14.09%
ROA(5y)-9.07%
ROE(3y)-42.99%
ROE(5y)-26.95%
ROIC(3y)N/A
ROIC(5y)N/A
TNDM Yearly ROA, ROE, ROICTNDM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

The Gross Margin of TNDM (52.22%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of TNDM has remained more or less at the same level.
TNDM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 52.22%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.92%
GM growth 5Y-0.58%
TNDM Yearly Profit, Operating, Gross MarginsTNDM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

2

2. Health

2.1 Basic Checks

TNDM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TNDM has been increased compared to 1 year ago.
Compared to 5 years ago, TNDM has more shares outstanding
The debt/assets ratio for TNDM is higher compared to a year ago.
TNDM Yearly Shares OutstandingTNDM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
TNDM Yearly Total Debt VS Total AssetsTNDM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of 0.52, we must say that TNDM is in the distress zone and has some risk of bankruptcy.
TNDM has a Altman-Z score (0.52) which is comparable to the rest of the industry.
A Debt/Equity ratio of 2.02 is on the high side and indicates that TNDM has dependencies on debt financing.
TNDM has a Debt to Equity ratio of 2.02. This is amonst the worse of the industry: TNDM underperforms 85.56% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.02
Debt/FCF N/A
Altman-Z 0.52
ROIC/WACCN/A
WACC7.76%
TNDM Yearly LT Debt VS Equity VS FCFTNDM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

TNDM has a Current Ratio of 2.30. This indicates that TNDM is financially healthy and has no problem in meeting its short term obligations.
TNDM has a Current ratio (2.30) which is in line with its industry peers.
TNDM has a Quick Ratio of 1.81. This is a normal value and indicates that TNDM is financially healthy and should not expect problems in meeting its short term obligations.
TNDM's Quick ratio of 1.81 is in line compared to the rest of the industry. TNDM outperforms 48.13% of its industry peers.
Industry RankSector Rank
Current Ratio 2.3
Quick Ratio 1.81
TNDM Yearly Current Assets VS Current LiabilitesTNDM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

6

3. Growth

3.1 Past

TNDM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.13%, which is quite good.
TNDM shows a strong growth in Revenue. In the last year, the Revenue has grown by 27.66%.
The Revenue has been growing by 21.01% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)19.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.76%
Revenue 1Y (TTM)27.66%
Revenue growth 3Y10.19%
Revenue growth 5Y21.01%
Sales Q2Q%21.58%

3.2 Future

TNDM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.11% yearly.
TNDM is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.41% yearly.
EPS Next Y0.81%
EPS Next 2Y22.86%
EPS Next 3Y25.32%
EPS Next 5Y20.11%
Revenue Next Year10.43%
Revenue Next 2Y10.68%
Revenue Next 3Y10.26%
Revenue Next 5Y9.41%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TNDM Yearly Revenue VS EstimatesTNDM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
TNDM Yearly EPS VS EstimatesTNDM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TNDM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TNDM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNDM Price Earnings VS Forward Price EarningsTNDM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNDM Per share dataTNDM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A more expensive valuation may be justified as TNDM's earnings are expected to grow with 25.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.86%
EPS Next 3Y25.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TNDM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TANDEM DIABETES CARE INC

NASDAQ:TNDM (6/16/2025, 11:43:35 AM)

20.7

-0.06 (-0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-30 2025-04-30/amc
Earnings (Next)07-30 2025-07-30/amc
Inst Owners111.69%
Inst Owner Change2.74%
Ins Owners0.64%
Ins Owner Change2.82%
Market Cap1.38B
Analysts73.79
Price Target36.57 (76.67%)
Short Float %11.68%
Short Ratio4.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)49.29%
Min EPS beat(2)-5.69%
Max EPS beat(2)104.27%
EPS beat(4)3
Avg EPS beat(4)31.89%
Min EPS beat(4)-5.69%
Max EPS beat(4)104.27%
EPS beat(8)4
Avg EPS beat(8)16.24%
EPS beat(12)4
Avg EPS beat(12)-145.39%
EPS beat(16)6
Avg EPS beat(16)-114.79%
Revenue beat(2)2
Avg Revenue beat(2)7.17%
Min Revenue beat(2)4.37%
Max Revenue beat(2)9.97%
Revenue beat(4)4
Avg Revenue beat(4)6.86%
Min Revenue beat(4)4.37%
Max Revenue beat(4)9.97%
Revenue beat(8)5
Avg Revenue beat(8)3.05%
Revenue beat(12)5
Avg Revenue beat(12)0.97%
Revenue beat(16)9
Avg Revenue beat(16)2.39%
PT rev (1m)1.19%
PT rev (3m)-20.6%
EPS NQ rev (1m)0.41%
EPS NQ rev (3m)-24.34%
EPS NY rev (1m)0%
EPS NY rev (3m)-15.28%
Revenue NQ rev (1m)0.07%
Revenue NQ rev (3m)-4.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.4
P/FCF N/A
P/OCF 98.89
P/B 8.88
P/tB 8.88
EV/EBITDA N/A
EPS(TTM)-1.48
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)0.21
OCFY1.01%
SpS14.76
BVpS2.33
TBVpS2.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.94%
ROE -118.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 52.22%
FCFM N/A
ROA(3y)-14.09%
ROA(5y)-9.07%
ROE(3y)-42.99%
ROE(5y)-26.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.92%
GM growth 5Y-0.58%
F-Score6
Asset Turnover1.07
Health
Industry RankSector Rank
Debt/Equity 2.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 380.11%
Cap/Sales 6.53%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.3
Quick Ratio 1.81
Altman-Z 0.52
F-Score6
WACC7.76%
ROIC/WACCN/A
Cap/Depr(3y)341.43%
Cap/Depr(5y)300.44%
Cap/Sales(3y)6.42%
Cap/Sales(5y)5.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.76%
EPS Next Y0.81%
EPS Next 2Y22.86%
EPS Next 3Y25.32%
EPS Next 5Y20.11%
Revenue 1Y (TTM)27.66%
Revenue growth 3Y10.19%
Revenue growth 5Y21.01%
Sales Q2Q%21.58%
Revenue Next Year10.43%
Revenue Next 2Y10.68%
Revenue Next 3Y10.26%
Revenue Next 5Y9.41%
EBIT growth 1Y37.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year127.71%
EBIT Next 3Y45.19%
EBIT Next 5Y30.24%
FCF growth 1Y-62.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.22%
OCF growth 3Y-39.87%
OCF growth 5Y-10.38%